ZyVersa Therapeutics (ZVSA) Competitors $0.55 -0.02 (-3.31%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.54 -0.01 (-1.82%) As of 07/15/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. MTVA, ALVR, SONN, NXTC, LPTX, IMCC, SNPX, BTAI, NERV, and PHIOShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include MetaVia (MTVA), AlloVir (ALVR), Sonnet BioTherapeutics (SONN), NextCure (NXTC), Leap Therapeutics (LPTX), IM Cannabis (IMCC), Synaptogenix (SNPX), BioXcel Therapeutics (BTAI), Minerva Neurosciences (NERV), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Its Competitors MetaVia AlloVir Sonnet BioTherapeutics NextCure Leap Therapeutics IM Cannabis Synaptogenix BioXcel Therapeutics Minerva Neurosciences Phio Pharmaceuticals MetaVia (NASDAQ:MTVA) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do institutionals & insiders believe in MTVA or ZVSA? 1.4% of MetaVia shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, MTVA or ZVSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/AZyVersa TherapeuticsN/AN/A-$9.41MN/AN/A Does the media refer more to MTVA or ZVSA? In the previous week, ZyVersa Therapeutics had 2 more articles in the media than MetaVia. MarketBeat recorded 6 mentions for ZyVersa Therapeutics and 4 mentions for MetaVia. ZyVersa Therapeutics' average media sentiment score of 0.47 beat MetaVia's score of -0.13 indicating that ZyVersa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral ZyVersa Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, MTVA or ZVSA? MetaVia has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Do analysts prefer MTVA or ZVSA? MetaVia currently has a consensus price target of $7.50, indicating a potential upside of 1,023.60%. Given MetaVia's stronger consensus rating and higher possible upside, equities analysts clearly believe MetaVia is more favorable than ZyVersa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MTVA or ZVSA more profitable? ZyVersa Therapeutics' return on equity of -109.54% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -222.13% -123.85% ZyVersa Therapeutics N/A -109.54%-43.95% SummaryZyVersa Therapeutics beats MetaVia on 7 of the 11 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.77M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E RatioN/A20.2228.5719.58Price / SalesN/A291.25423.3593.84Price / CashN/A43.1536.0257.93Price / Book0.167.568.135.54Net Income-$9.41M-$55.11M$3.24B$257.73M7 Day Performance-14.22%3.81%0.16%-0.08%1 Month Performance-13.13%11.60%5.95%8.09%1 Year Performance-87.57%-2.11%26.09%13.02% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.1824 of 5 stars$0.55-3.3%N/A-87.6%$2.77MN/A0.002Analyst UpgradeMTVAMetaVia1.7322 of 5 stars$0.62-4.0%$7.50+1,105.6%N/A$12.69MN/A0.008ALVRAlloVirN/A$2.50-2.3%N/A-85.6%$12.61MN/A-0.12110High Trading VolumeSONNSonnet BioTherapeutics3.7412 of 5 stars$4.73+20.7%$20.00+322.8%+38.4%$12.41M$20K0.0010Trending NewsGap DownHigh Trading VolumeNXTCNextCure4.3506 of 5 stars$0.44+1.2%$3.50+693.5%+185.0%$12.22MN/A-0.2590Analyst ForecastLPTXLeap Therapeutics2.2261 of 5 stars$0.28-2.6%$3.38+1,089.2%-84.6%$12.07MN/A-0.1740Positive NewsGap DownIMCCIM Cannabis0.1599 of 5 stars$3.30+11.5%N/A+11.9%$11.97M$39.44M-5.16340SNPXSynaptogenix0.3183 of 5 stars$8.50+5.2%$14.00+64.7%+130.2%$11.82MN/A-0.844Positive NewsBTAIBioXcel Therapeutics4.1989 of 5 stars$1.90-1.6%$42.60+2,142.1%-90.3%$11.69M$2.27M-0.1490Positive NewsGap UpNERVMinerva Neurosciences4.1952 of 5 stars$1.64-0.6%$5.00+204.9%-46.0%$11.54MN/A2.009News CoveragePHIOPhio Pharmaceuticals2.5499 of 5 stars$2.55+6.3%$14.00+449.0%-49.0%$11.52MN/A-0.4010 Related Companies and Tools Related Companies MTVA Alternatives ALVR Alternatives SONN Alternatives NXTC Alternatives LPTX Alternatives IMCC Alternatives SNPX Alternatives BTAI Alternatives NERV Alternatives PHIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVSA Stock Alerts